In response to COVID-19, GHX is committed to helping ensure that our customers receive access to the data and information needed to help maintain critical supplies to serve patients and protect staff. Click to learn more
Log In

Approved in May 2018, Andexxa is the first and only available agent indicated for the reversal of the direct oral anticoagulants (DOACs). Previously, many health systems relied on the off-label use of the much less costly 4F-PCC.

Given its high cost, should hospital pharmacies add Andexxa to formulary for the reversal of DOACs during emergent bleeding?

Download this PDF for the Lumere team’s analysis of the evidence.

Watch a related video: Drug and Device Insights: Does the Evidence Support Andexxa’s Price Premium?

“Evidence Insight Spotlight: Andexxa”

Download Now